These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 16752073

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU.
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
    Sestak I, Sapunar F, Cuzick J.
    J Clin Oncol; 2009 Oct 20; 27(30):4961-5. PubMed ID: 19752338
    [Abstract] [Full Text] [Related]

  • 8. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J, Pritchard K, Goss P.
    Breast; 2007 Dec 01; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 12. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J, Ellis P.
    Cancer Lett; 2007 Apr 18; 248(2):165-74. PubMed ID: 16919870
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J, Johnson M, Seidman A.
    Semin Oncol; 2006 Dec 18; 33(6):672-80. PubMed ID: 17145347
    [Abstract] [Full Text] [Related]

  • 14. Tolerance of adjuvant letrozole outside of clinical trials.
    Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Grève J.
    Breast; 2008 Aug 18; 17(4):376-81. PubMed ID: 18455395
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
    Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Dec 20; 25(36):5715-22. PubMed ID: 17998546
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK, Nielsen DL, Lindberg H, Kamby C.
    Ugeskr Laeger; 2007 Jan 22; 169(4):297-9. PubMed ID: 17274922
    [Abstract] [Full Text] [Related]

  • 20. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 22; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.